×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VSTM – verastem, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VSTM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
12:04 am
vstm
Verastem, Inc. (NASDAQ: VSTM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Verastem, Inc. (NASDAQ: VSTM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/6
05:06 pm
vstm
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
Medium
Report
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
11/6
04:05 pm
vstm
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Medium
Report
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
11/1
12:18 pm
vstm
Verastem Oncology submits NDA for ovarian cancer treatment [Yahoo! Finance]
Low
Report
Verastem Oncology submits NDA for ovarian cancer treatment [Yahoo! Finance]
10/31
04:01 pm
vstm
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Medium
Report
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
10/31
07:30 am
vstm
Verastem Oncology to Participate in Upcoming Investor Conferences
Low
Report
Verastem Oncology to Participate in Upcoming Investor Conferences
10/18
10:35 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $13.00 price target on the stock.
High
Report
Verastem, Inc. (NASDAQ: VSTM) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $13.00 price target on the stock.
10/18
08:33 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
High
Report
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
06:26 pm
vstm
Form SC 13G/A Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
Medium
Report
Form SC 13G/A Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
11/14
04:56 pm
vstm
Form SCHEDULE 13G Verastem, Inc. Filed by: Nantahala Capital Management, LLC
Medium
Report
Form SCHEDULE 13G Verastem, Inc. Filed by: Nantahala Capital Management, LLC
11/14
04:39 pm
vstm
Form SC 13G/A Verastem, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Medium
Report
Form SC 13G/A Verastem, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
11/14
04:36 pm
vstm
Form SC 13G Verastem, Inc. Filed by: Alyeska Investment Group, L.P.
Medium
Report
Form SC 13G Verastem, Inc. Filed by: Alyeska Investment Group, L.P.
11/14
04:31 pm
vstm
Form SC 13G/A Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Medium
Report
Form SC 13G/A Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
11/14
03:34 pm
vstm
Form SC 13G/A Verastem, Inc. Filed by: Soleus Private Equity Fund III, L.P.
Low
Report
Form SC 13G/A Verastem, Inc. Filed by: Soleus Private Equity Fund III, L.P.
11/14
09:02 am
vstm
Form SC 13G/A Verastem, Inc. Filed by: Flynn James E
Low
Report
Form SC 13G/A Verastem, Inc. Filed by: Flynn James E
11/13
05:39 pm
vstm
Form SC 13G/A Verastem, Inc. Filed by: Stonepine Capital Management, LLC
Medium
Report
Form SC 13G/A Verastem, Inc. Filed by: Stonepine Capital Management, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/28
Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs
59.4%
1/8 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 43.3%
6/17 Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting 24.1%
10/23 Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress 21.6%
4/20 Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors 21.3%
2/3 Form SC 13G Verastem, Inc. Filed by: Point72 Asset Management, L.P. 14.2%
4/21 Form DEFA14A Verastem, Inc. 13.2%
3/5 Form 3 Verastem, Inc. For: Mar 03 Filed by: Kolchinsky Peter 12.3%
7/10 Form SC 13G/A Verastem, Inc. Filed by: BlackRock Inc. 10.7%
5/10 Verastem Inc (NASDAQ: VSTM) had its price target lowered by analysts at BTIG Research to $8.00. They now have a "buy" rating on the stock. 9.5%
1/8 Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 43.3%
6/17 Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting 24.1%
10/23 Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress 21.6%
4/20 Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors 21.3%
2/3 Form SC 13G Verastem, Inc. Filed by: Point72 Asset Management, L.P. 14.2%
4/21 Form DEFA14A Verastem, Inc. 13.2%
3/5 Form 3 Verastem, Inc. For: Mar 03 Filed by: Kolchinsky Peter 12.3%
7/10 Form SC 13G/A Verastem, Inc. Filed by: BlackRock Inc. 10.7%
5/10 Verastem Inc (NASDAQ: VSTM) had its price target lowered by analysts at BTIG Research to $8.00. They now have a "buy" rating on the stock. 9.5%
TOP News Decliners
4/27
Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I
-51.4%
5/9 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.460 ActVsEst (0.060) - Miss -28.8%
3/11 Form 10-K Verastem, Inc. For: Dec 31 -26.1%
6/20 Verastem Oncology Announces Leadership Changes -17.2%
3/16 Verastem Inc (NASDAQ: VSTM) had its price target raised by analysts at HC Wainwright from $2.50 to $2.75. They now have a "buy" rating on the stock. -16.8%
8/1 Form 8-K Verastem, Inc. For: Jul 29 -16.7%
3/6 Form SC 13G/A Verastem, Inc. Filed by: Ridgeback Capital Investments L.P. -16.0%
10/29 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus -0.420 ActVsEst 0.070 - Beat -14.3%
4/28 Verastem Inc (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.75 price target on the stock. -14.2%
4/23 Form 8-K Verastem, Inc. For: Apr 23 -10.3%
5/9 Q1/2019 3/31/2019 EPS -0.520 ZacksConsensus -0.460 ActVsEst (0.060) - Miss -28.8%
3/11 Form 10-K Verastem, Inc. For: Dec 31 -26.1%
6/20 Verastem Oncology Announces Leadership Changes -17.2%
3/16 Verastem Inc (NASDAQ: VSTM) had its price target raised by analysts at HC Wainwright from $2.50 to $2.75. They now have a "buy" rating on the stock. -16.8%
8/1 Form 8-K Verastem, Inc. For: Jul 29 -16.7%
3/6 Form SC 13G/A Verastem, Inc. Filed by: Ridgeback Capital Investments L.P. -16.0%
10/29 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus -0.420 ActVsEst 0.070 - Beat -14.3%
4/28 Verastem Inc (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.75 price target on the stock. -14.2%
4/23 Form 8-K Verastem, Inc. For: Apr 23 -10.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: